ClinicalTrials.gg
Not yet recruitingNCT07895992Updated Nov 12, 2026

SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study

A Phase 3 interventional study of SHR-A2009 + bevacizumab and Sacituzumab Tirumotecan in Non-squamous Non-small Cell Lung Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Study contact changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
490
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 15 under way, 3 of them phase 3. Bevacizumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
25th of 149
490 · median 56
Started
2026
with 2 others
Phase 3
29 of 150
1 open now
Primary completion
2028-12
later than 12 of 14 live
Registered
151st of 150
by date

Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, this one is the 25th largest by planned enrollment of the 149 interventional ones that give a count, is one of 3 that started in 2026, is one of 29 in phase 3, reaches primary completion later than 12 of the 14 other live ones, and was the 151st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined bevacizumab versus Sacituzumab Tirumotecan in the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer

03

Conditions studied

  • Non-squamous Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the in writing ; the age at the time of signing the informed consent form is 18-75 years old ( including both ends ), both men and women can.

    The score was 0 or 1.

  2. Participants with locally advanced or non-squamous non-small cell lung cancer confirmed by histology or cytology.
  3. Adequate bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Anti-tumor therapy such as chemotherapy, biological therapy, targeted therapy, immunotherapy or other unlisted clinical research drugs or treatments were received within 4 weeks before the first medication.
  2. Untreated or active central nervous system tumor
  3. Imaging showed that the tumor invaded important organs or tumor surrounding / invasion of large blood vessels or there was obvious necrosis / cavity, which was judged by the researchers to have a risk of bleeding.
  4. History of interstitial pneumonia or participants who cannot rule out interstitial pneumonia ; or other moderate to severe lung diseases ; or received previous pneumonectomy surgery
  5. Participants with severe cardiovascular and cerebrovascular diseases
  6. Have a history of severe bleeding tendency or coagulation dysfunction ; bleeding symptoms with significant clinical significance occurred within 3 months before the first medication.
  7. Arterial and venous thrombosis events occurred within 6 months before the first administration ;
  8. test positive
  9. Participants with active or C
  10. Severe infection occurred within 4 weeks before the first administration
  11. Allergy to any component of the treatment regimen
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
490 participants (estimated)

Study arms

  • Experimental
    SHR-A2009 + bevacizumab

    Drug: SHR-A2009 + bevacizumab

  • Active comparator
    Sacituzumab Tirumotecan

    Drug: Sacituzumab Tirumotecan

Interventions

06

What researchers measure

Primary outcomes

  1. PFS

    Time frame: about 24 months

Secondary outcomes

  1. The incidence and grade of adverse events;

    Time frame: about 24 months

  2. OS

    Time frame: about 24 months

  3. ORR

    Time frame: about 24 months

  4. DoR

    Time frame: about 24 months

  5. DCR

    Time frame: about 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 25 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 26, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: •••6365→•••2973. See the current contact
Nov 12, 2026
Registered
First appeared on the registry
Oct 26, 2026
Show all 2 updates
  1. Nov 12, 2026
    Contact Study contact's phone or email changed: •••6365→•••2973. See the current contact
  2. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07895992
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Yijing Chen
Contact
yijing.chen.yc510@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ruzaltatug rezetecan · Bevacizumab

Start the discussion